<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 258 from Anon (session_user_id: d71a1a06d89dc6769f9068429b6bc54d5005913d)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 258 from Anon (session_user_id: d71a1a06d89dc6769f9068429b6bc54d5005913d)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><ul><li><span style="font-size:14px;line-height:21px;">The normal function of DNA methylation at CpG island is silencing of gene expression and helping to maintain genomic stability.</span></li>
<li><span style="line-height:21px;font-size:14px;">Hypermetylation leads to </span><span style="line-height:21px;font-size:14px;">silence tumour suppressor genes in cancer.</span></li>
<li><span style="line-height:21px;font-size:14px;">Hypometylation of CpG poor pormoters cause activation of oncogene</span></li>
<li><span style="line-height:21px;font-size:14px;">The normal function of DNA methylation in intergenic regions and repetitive elements is to maintein genomic integrity.</span></li>
<li><span style="font-size:14px;line-height:21px;">In repetive regions, DNA methylation contribute to maintain genomic integrity, e.g.  </span><span style="font-size:14px;line-height:21px;">preventing transposition, </span><span style="font-size:14px;line-height:21px;">and avoiding transcriptional interference from strong promoters</span></li>
<li><span style="font-size:14px;line-height:21px;">In intergenic regions, DNA methylation  contribute to maintain genomic integrity, e.g. </span><span style="font-size:14px;line-height:21px;">silencing cryptic transcription start sites or cryptic splice sites.</span></li>
<li><span style="line-height:21px;font-size:14px;">Explain how disruption of DNA methylation in intergenic regions and repetitive elements contributes to disease.</span></li>
<li><span style="font-size:14px;line-height:21px;">DNA hypomethylation of repeats and intergenic interval </span><span style="font-size:14px;line-height:21px;"><span style="font-size:14px;line-height:21px;">lead to genomic instability; </span></span><span style="line-height:21px;font-size:14px;"> activation of repeats and transposition, </span><span style="line-height:21px;font-size:14px;">activation of cryptic promoters and disruption to </span><span style="line-height:21px;font-size:14px;">neighbouring genes.</span></li>
</ul></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><ul><li>Decitabine is a kind of DNA-demethylating agent (<span>DNA methyltransferase</span> inhibitor). </li>
<li>Decitabine inhibit hypermethylation of tumor-suppressor gene whose job is to stop the uncontrolled cell growth that couses cancer.</li>
<li>Decitabine is <span style="line-height:21px;font-size:14px;">used to treat myelodysplastic syndromes, precursors of acute myelogenous leukaemia.</span></li>
</ul></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><div style="line-height:21px;font-size:14px;">
<ul><li><span style="font-size:14px;line-height:21px;">Unlike other forms of gene regulation (those involving transcription factors, for example), epigenetic changes are passed on during cell division to daughter and granddaughter cells until they are actively erased. Once erased, though, they do not return. It might therefore be that epigenetic therapies can effect changes which stop a cancer growing without having to kill all its cells.</span></li>
<li><span style="line-height:21px;font-size:14px;">Sensitive periods during early development are when  </span><span style="line-height:21px;font-size:14px;">epigenetic reprogramming occurs and importantly epigenetic </span><span style="line-height:21px;font-size:14px;">marks are reestablished post-implantation.</span></li>
<li><span style="line-height:21px;font-size:14px;">Not sensitive period (epigenetic marks are being </span><span style="line-height:21px;font-size:14px;">established), but cancer can result from a single cell </span><span style="line-height:21px;font-size:14px;">with an uncorrected error</span></li>
<li><span style="line-height:21px;font-size:14px;"><span>Treating patients during sensitivel periods of early development can alter the pattern of DNA methylation, resulting in potentially adverse biological effects such as aberrant gene expression. </span></span></li>
</ul></div></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><ul><li><span style="line-height:21px;font-size:14px;">On the maternal allele, ICR is not methylated and CTCF can bind at ICR. </span><span style="font-size:14px;line-height:21px;">CTCF is an insulator protein, and insulates Igf2 from downstream </span><span style="font-size:14px;line-height:21px;">enhancers.</span></li>
<li><span style="font-size:14px;line-height:21px;">On the paternal allele,  DNA methylation at ICR blocks binding of CTCF binding, and </span><span style="font-size:14px;line-height:21px;">DNA methylation spreads to H19 promoter to </span><span style="font-size:14px;line-height:21px;">silence and enhancers can access Igf2 to activate.</span></li>
<li><span style="font-size:14px;line-height:21px;">Hypermethylation of ICR, Igf2 overexpression in Wilm’s tumour.</span></li>
<li>
<p>Alterations in DNA methylation at ICRs (hypo or hypermethylation), can result in loss of expression of growth restricting genesor overexpression of growth promoting genes.</p>
</li>
</ul></div>
  </body>
</html>